Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers
Clinical Infectious Diseases2022Vol. 76(3), pp. e533–e536
Citations Over TimeTop 16% of 2022 papers
Roos S. G. Sablerolles, Wim J. R. Rietdijk, Abraham Goorhuis, Douwe F. Postma, Leo G. Visser, Katharina S. Schmitz, Daryl Geers, Susanne Bogers, Eva van Haren, Marion Koopmans, Virgil A. S. H. Dalm, Neeltje A. Kootstra, Anke Huckriede, Renate Akkerman, Martin Beukema, Melvin Lafeber, Debbie van Baarle, Rory D. de Vries, P.H.M. van der Kuy, Corine H. GeurtsvanKessel
Abstract
The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2-specific binding antibodies, neutralizing antibodies, and T cells are detectable 5 months after boosting, although waning of antibodies and limited cross-reactivity with Omicron BA.1 was observed.
Related Papers
- → Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge(1997)153 cited
- → Cross-Protective Capacity of Japanese Encephalitis (JE) Vaccines Against Circulating Heterologous JE Virus Genotypes(2012)74 cited
- → Comparison between in vitro neutralization titres and in vivo protection against homologous and heterologous challenge induced by vaccines prepared from two serologically distinct variants of foot-and-mouth disease virus, serotype A22(1992)19 cited
- → Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines(1995)80 cited
- USE OF THE FLUORESCENT ANTIBODY METHOD IN STUDYING ANTIGEN-ANTIBODY REACTION IN TISSUES. STUDY OF LOCALIZATION OF ANTIRENAL AND ANTIHEPATIC ANTIBODIES IN HOMO- AND HETEROLOGOUS TISSUES(1964)